TPST — Tempest Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on TPST
| date | signal | measured base rate |
|---|---|---|
| 2026-06-23 | Conviction buy by an officer insider | -1.03% over 21 days · t = -2.24 · n = 1,083 statistically distinguishable from its control group |
| 2026-03-25 | Conviction buy by an officer insider | -1.03% over 21 days · t = -2.24 · n = 1,083 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-03-24 | Angel Matthew CEO and President | Open-market purchase | 231.5K | 2.16 | 500.0K |
| 2026-03-24 | Angel Matthew CEO and President | Open-market purchase | 231.5K | 2.16 | 500.0K |
| 2024-08-12 | Versant Vantage II, L.P. | Open-market sale | 388.0K | 1.10 | 426.8K |
| 2024-08-12 | Versant Ventures VI GP-GP, LLC | Open-market sale | 388.0K | 1.10 | 426.8K |
| 2024-08-12 | Versant Ventures IV, LLC | Open-market sale | 388.0K | 1.10 | 426.8K |
| 2024-08-12 | Versant Side Fund IV, L.P. | Open-market sale | 388.0K | 1.10 | 426.8K |
| 2024-08-12 | Versant Ventures VI GP, L.P. | Open-market sale | 388.0K | 1.10 | 426.8K |
| 2024-08-12 | Versant Venture Capital VI, L.P. | Open-market sale | 388.0K | 1.10 | 426.8K |
| 2024-08-12 | Versant Venture Capital IV, L.P. | Open-market sale | 388.0K | 1.10 | 426.8K |
| 2024-08-12 | Versant Vantage II GP-GP, LLC | Open-market sale | 388.0K | 1.10 | 426.8K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 383.6K | 233.9K |
| GEODE CAPITAL MANAGEMENT, LLC | 142.7K | 87.0K |
| VANGUARD FIDUCIARY TRUST CO | 113.0K | 68.9K |
| BlackRock, Inc. | 64.1K | 39.1K |
| FMR LLC | 54.5K | 33.2K |
| SABBY MANAGEMENT, LLC | 29.3K | 17.9K |
| NORTHERN TRUST CORP | 23.0K | 14.1K |
| DIMENSIONAL FUND ADVISORS LP | 18.8K | 11.4K |
| UBS Group AG | 7.4K | 4.5K |
| Tower Research Capital LLC (TRC) | 4.6K | 2.8K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Tempest Therapeutics, Inc. (TPST) filed form 8-K · 2026-08-18 · SEC EDGAR
- Tempest Therapeutics, Inc. (TPST) filed form 8-K · 2026-08-13 · SEC EDGAR
- Tempest Therapeutics, Inc. (TPST) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about TPST
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →